We are very proud to share our last piece published in the March issue of the Lancet Oncology The article entitled "Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?" has been written by Nicolas André from the Department of Pediatric Oncology, La Timone University, Hospital of Marseille, APHM, Marseille 13005, France; Guy Buyens from the The Anticancer Fund, Brussels, Belgium; Eric Bouffet from the Division of Neuro-oncology,Department of Pediatric Hematology-Oncology, Hospital for Sick Children, Toronto, ON, Canada (EB); David Walker from the University of Nottingham, Nottingham, UK; and Matthew D Dun from the Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine & Wellbeing, University of Newcastle, Callaghan ; Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia

It tells the story of ONC2101 and how its unusual clinical developpement has triggered new innitiatve to try to promote its access to patients. We then question what can be re-used from theses incitatives for other new drus.

you can have access the full paper here